Biocryst Pharmaceuticals (BCRX) Operating Expenses (2010 - 2026)

Biocryst Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $858.0 million for Q1 2026.

• Quarterly Operating Expenses rose 590.24% year-over-year to $858.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 169.51% YoY) and the FY2025 annual result came in at $533.8 million, up 17.78% from the prior year.
• Operating Expenses was $858.0 million for Q1 2026 at Biocryst Pharmaceuticals, up from $146.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $858.0 million in Q1 2026 and bottomed at $93.3 million in Q3 2022.
• A 5-year average of $158.8 million and a median of $109.4 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slipped 2.69% — and 2026, when it surged 590.24%.
• Biocryst Pharmaceuticals' Operating Expenses stood at $125.9 million in 2022, then advanced by 8.12% to $136.1 million in 2023, then decreased by 0.02% to $136.0 million in 2024, then grew by 7.44% to $146.2 million in 2025, then jumped by 487.0% to $858.0 million in 2026.
• Business Quant data shows BCRX's Operating Expenses at $858.0 million in Q1 2026, $146.2 million in Q4 2025, and $129.8 million in Q3 2025.